Fulcrum therapeutics® to host virtual key opinion leader webcast featuring losmapimod for facioscapulohumeral muscular dystrophy (fshd)

Event to discuss unmet need in fshd, key measures of disease progression and phase 3 reach trial

FULC Ratings Summary

FULC Quant Ranking